- Home
- IAE vs IFRX Comparison
IAE vs IFRX Comparison
Compare IAE & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IAE
Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | IAE | IFRX |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.3M | 86.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | IAE | IFRX |
|---|---|---|
| Price | $7.31 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 46.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.31 | $0.71 |
| 52 Week High | $6.45 | $2.77 |
Technical Indicators
Market Signals| Indicator | IAE | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 43.13 |
| Support Level | $7.20 | $1.00 |
| Resistance Level | $7.35 | $1.08 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 51.13 | 38.87 |
Price Performance
Historical ComparisonAbout IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.